Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Oxaliplatin for Transitional Cell Carcinoma with Renal Impairment
2005-000192-17Phase 4Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Apr 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemcitabine and oxaliplatin in transitional cell carcinoma (TCC), sponsored by Barts Health NHS Trust. Primary endpoint: Treatment response. Started Apr 2005; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2005-000192-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000192-17.